Anti-Human CA-125/0772P Recombinant Antibody (117.1) (CAT#: TAB-1394CL)

This antibody preferentially binds to cell-associated CA-125/0772P polypeptides relative to shed CA-125/0772P polypeptides, which can be used for preventing, managing, treating or ameliorating one or more symptoms associated with a CA-125/0772P-related disorder and a cell proliferative disorder, such as cancer, e.g., ovarian cancer.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA
FC

Figure 1 A representative plot from a FACS competition assay of shed CA 125/O772P concentrations versus percent positive cells for, in this instance, 117.1 antibody and Ml 1 antibody control (squares).

Figure 1 A representative plot from a FACS competition assay of shed CA 125/O772P concentrations versus percent positive cells for, in this instance, 117.1 antibody and Ml 1 antibody control (squares).

Ml 1 can be competed for binding to OVCAR-3 cells even at low concentrations of shed CA 125/O772P (IC50 = 0.003mg/ml) while 117.1 cannot be competed, even at high concentrations of shed CA 125/O772P (IC50 greater than 1 mg/ml).

ADCC

Figure 2 A representative plot from an ADCC assay of percent lysis versus antibody concentration for 117.1 antibody (average of 4 separate donors).

Figure 2 A representative plot from an ADCC assay of percent lysis versus antibody concentration for 117.1 antibody (average of 4 separate donors).

As shown in the figure, antibody 117.1 mediates specific lysis of OVCAR-3 cells in a dose-dependent manner.

FuncS

Figure 3 In vivo evaluation of ¹³¹I-labeled 776.1.

Figure 3 In vivo evaluation of ¹³¹I-labeled 776.1.

NCR nu/nu mice bearing OVCAR-3 tumors were treated with either saline, 100 μCi [¹³¹I]776.1 IgG1, 300 μCi [¹³¹I]776.1 IgG1, or 17 μg unlabeled 776.1 IgG1 (same protein dose as in the 300 μCi [¹³¹I]776.1 IgG1 group). Treatment was a single dose administered intravenously on day 0. The specific activity of [¹³¹I]776.1 was 15 mCi/mg with an immunoreactivity of 51% post- labeling. Results are shown as mean tumor volume+/-SD for 10 mice total per group. Mean tumor size at the beginning of treatment was 199 mm³ for all groups.


Specifications

  • Immunogen
  • CA-125/0772P
  • Host Species
  • Mouse
  • Specificity
  • Human
  • Clone
  • 117.1
  • Applications
  • FC, ADCC, FuncS
  • Related Disease
  • CA-125/0772P-related disorder and CA-125/O772P-positive tumors

Applications

  • Application Notes
  • This antibody has been tested for use in Flow Cytometry, Antibody-dependent Cellular Cytotoxicity Assay and Functional Assay.

Target

  • Alternative Names
  • CA-125/0772P

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 117.1"

See other products for "CA-125/0772P"

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-1394CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare